Adaptive Biotechnologies to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Rhea-AI Summary
Adaptive Biotechnologies (Nasdaq: ADPT) will participate in the Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY. Management is scheduled for a fireside chat on Tuesday, September 15, 2026, at 1:50 p.m. PT / 4:50 p.m. ET. A live and archived webcast will be available in the Investors section of the company’s website. Adaptive Biotechnologies is a commercial-stage biotechnology company using its proprietary immune medicine platform to develop diagnostics and treatments across Minimal Residual Disease (MRD) and Immune Medicine business segments.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 29 | 2Q26 earnings | Positive | +7.2% | Revenue growth, narrowed adjusted EBITDA loss, and raised full-year MRD guidance |
| Jul 09 | Earnings date notice | Neutral | -3.4% | Announcement set the date for second-quarter financial results and webcast |
| Jun 17 | Convertible notes offering | Negative | -2.6% | Upsized convertible notes offering included share repurchase and refinancing uses |
| Jun 15 | Business separation plan | Neutral | -1.4% | Company announced planned separation of MRD and Immune Medicine businesses |
| Jun 15 | Convertible notes offering | Negative | -1.4% | Proposed convertible notes would fund capped calls, debt repayment, and corporate purposes |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Historical reactions were mixed: the July 29 earnings release rose 7.18%, while the July 9 earnings-date notice and two June offering announcements declined.
Key Terms
minimal residual disease medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SEATTLE, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY.
Adaptive Biotechnologies’ management is scheduled to participate in a fireside chat on Tuesday, September 15, 2026, at 1:50 p.m. Pacific Time / 4:50 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.adaptivebiotech.com.
About Adaptive Biotechnologies
Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business segments: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer and autoimmune disorders. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.
ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations and FP&A
201-396-1687
investors@adaptivebiotech.com
ADAPTIVE MEDIA
Erica Jones, Associate Corporate Communications Director
206-279-2423
media@adaptivebiotech.com
